The FDA is announcing the availability of final guidance for industry entitled “Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document.” The guidance clarifies where within the new drug application (NDA) and biologics license application (BLA) common technical document (CTD) format to include an integrated summary of effectiveness (ISE) and integrated summary of safety (ISS), and it addresses other related FDA requirements.